A Phase 2 interventional study of Tamsulosin and 5-hidroxitriptophan in BPH and LUTS(Lower Urinary Tract Symptoms), sponsored by Clinical Academic Center (2CA-Braga). Recruiting at 1 site in Portugal. Open to male participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-01-06.
Sponsored by Clinical Academic Center (2CA-Braga) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Benign prostatic hyperplasia (BPH) is one of the most prevalent human diseases and a major cause of lower urinary tract symptoms (LUTS). Some men respond to current medical treatment (mainly α-1 adrenoreceptor antagonists and 5 α-reductase inhibitors), but a large proportion of patients continues to need a surgical procedure to treat resistant LUTS or even more serious complications of BPH, creating the emerging necessity for novel pharmacological therapies.
Oxitriptan may have a possible positive effect on BPH associated symptoms with probably no impact in sexual function (which is a common side effect of the current drugs for BPH associated symptoms). Also, improvement in symptoms could be higher than that of current drugs used for this condition.
This is a single-center parallel group, randomized clinical trial. The study will take place in Hospital de Braga (Urology department). Eligible patients will be randomized to receive tamsulosin 0.4mg (once a day, q.d.) or 5-HTP (5-hidroxitriptophan) 100mg (three times a day, t.i.d.), for 6 months.
419 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.
This study's planned enrollment of 70 is below the median of 100 across 273 interventional studies indexed under Lower Urinary Tract Symptoms.
Browse Lower Urinary Tract Symptoms studies →Clinical Academic Center (2CA-Braga) is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tamsulosin 0.4mg (once a day) for 6 months.
Drug: Tamsulosin
5-hidroxitriptophan 100 mg (3 times a day) for 6 months.
Drug: 5-hidroxitriptophan
Oral medication, once a day for 6 months.
Also known as: Omnic
Oral medication, 3 times a day for 6 months.
Also known as: Cincofarm
International Prostate Symptom Score (IPSS)
Evaluate the effect of tryptophan supplementation on lower urinary tract symptoms (LUTS)
Time frame: Change from baseline to day 1, 1-month, 3- month and EOT (6-month)
Qmax
Urine maximum flow rate
Time frame: Change from baseline to EOT (6-month)
IIEF-5
Erectile function, assessed by International Index of Erectile Function-5 (IIEF-5)
Time frame: Change from baseline to EOT (6-month)
Prostate volume
Prostate volume (in cc), assessed by trans-rectal ultra-sound
Time frame: Change from baseline to EOT (6-month)
question 8 of the IPSS
quality of life due to urinary symptoms (question 8 of the IPSS).
Time frame: Change from baseline to EOT (6-month)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lower Urinary Tract Symptoms →
Clinical Academic Center (2CA-Braga)